<DOC>
	<DOCNO>NCT02449902</DOCNO>
	<brief_summary>The study design evaluate efficacy safety TX-12-004-HR 10 μg treat moderate severe symptom vaginal atrophy associate menopause 14 day treatment , estimate effect size variability vulvovaginal atrophy endpoint . In addition , systemic exposure estradiol single multiple dos TX-12-004-HR investigate .</brief_summary>
	<brief_title>TXV13-01 Estradiol Vaginal Softgel Capsules Treating Postmenopausal Women With Symptoms Vulvar Vaginal Atrophy</brief_title>
	<detailed_description>This study randomize , double-blind , placebo-controlled trial evaluate safety efficacy TX-12-004-HR formulation reduce moderate severe symptom vaginal atrophy associate menopause investigate systemic exposure estradiol follow daily intravaginal administration TX-12-004-HR 14 day . Postmenopausal subject meet study entry criterion randomize one two treatment group ( TX-12-004-HR Placebo ) . During Screening period subject ask self-assess symptom vulvar and/or vaginal atrophy , include vaginal dryness , vaginal and/or vulvar irritation/itching , dysuria , vaginal pain associate sexual activity vaginal bleeding associate sexual activity . Subjects least one self-assessed moderate severe symptom vulvar and/or vaginal atrophy identify subject bothersome eligible participate study .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Be female 40 75 year ( time randomization ) willing participate study , document signing informed consent form . 2 . Be postmenopausal woman . Postmenopausal define least 12 month spontaneous amenorrhea 12 month post bilateral oophorectomy , without hysterectomy ( documented operative report patient report ) . Women ≥ 60 year age hysterectomy without bilateral oophorectomy prior natural menopause consider menopausal . 3 . Have baseline evaluation requirement : ≤5 % superficial cell vaginal smear cytology Vaginal pH &gt; 5.0 Estradiol level ≤ 50 pg/ml At least one selfassessed moderate severe symptom vulvar and/or vaginal atrophy follow list identify subject bothersome : Vaginal dryness Vaginal pain associate sexual activity Vaginal and/or vulvar irritation/itching Dysuria Vaginal bleeding associate sexual activity ( absence vs. presence ) 4 . Have Body Mass Index ( BMI ) less equal 34 kg/m2 . ( BMI value round near integer [ e.g. , 34.4 round 34 , 26.5 round 27 ] ) . 5 . Be willing abstain use product ( study medication ) contain estrogen throughout study participation . 6 . Be judge Principal Investigator Subinvestigator otherwise generally good health base prestudy medical evaluation perform within 28 day prior initial dose study medication . The medical evaluation finding must include : normal nonclinically significant physical examination , include vital sign ( sit blood pressure , heart rate , respiratory rate temperature ) . normal nonclinically significant pelvic examination . mammogram show sign significant disease ( perform within previous 9 month prior initial dose study medication ) . An acceptable mammogram define mammogram mass finding identify suspicious malignancy . The site must obtain copy official report subject 's study file , must verify mammogram available need additional assessment . normal nonclinically significant clinical breast examination . An acceptable breast examination define mass finding identify suspicious malignancy . normal Screening Papanicolaou ( `` Pap '' ) smear ( ASCUS high risk human papillomavirus ( HPV ) negative acceptable ) . within normal limit nonclinically significant laboratory evaluation result sit systolic blood pressure ≤140 mmHg diastolic blood pressure ≤90 mmHg Screening . A subject may take two antihypertensive medication . 7 . Be willing abstain sexual activity use vaginal douching within 24 hour prior screen Visit 3 vaginal pH measurement . 1 . Be currently hospitalize . 2 . Have history thrombosis deep vein artery thromboembolic disorder . 3 . Have history coronary artery cerebrovascular disease . 4 . Have history liver kidney dysfunction/disorder . 5 . Have history gallbladder dysfunction/disorders ( e.g. , cholangitis , cholecystitis ) , unless gallbladder remove . 6 . Have history diabetes , thyroid disease ( subject dietcontrolled diabetes , control hypothyroid disease Screening exclude ) , endocrinological disease . 7 . Have history estrogendependent neoplasia . 8 . Have history atypical ductal hyperplasia breast . 9 . Have history undiagnosed vaginal bleeding . 10 . Have vaginal infection require treatment 11 . Have history endometrial hyperplasia uterine/endometrial , breast ovarian cancer . 12 . Have history malignancy within last 5 year , exception basal cell ( exclude within 1 year ) noninvasive squamous cell ( exclude within 1 year ) carcinoma skin . 13 . Have history cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychological , musculoskeletal disease disorder clinically significant opinion Principal Investigator Medical SubInvestigator . 14 . Have contraindication estrogen therapy allergy use estradiol component investigational drug . 15 . Use 15 cigarette per day . 16 . Have history drug and/or alcohol abuse within one year start study . 17 . Have use , within 28 day prior Screening , plan use study , prescription overthecounter ( OTC ) medication ( include herbal product ) would expect interact estradiol therapy . 18 . Use type vaginal preparation ( include lubricant moisturizers ) within 14 day prior Screening . 19 . Have use estrogen alone estrogen/progestin following time period : Vaginal hormonal product ( ring , cream , gel ) within 3 month prior Screening . Transdermal estrogen alone estrogen/progestin product within 8 week prior Screening . Oral estrogen and/or progestin therapy within 8 week prior Screening . Progestational implant , estrogen estrogen/progestational injectable drug therapy within 3 month prior Screening . Estrogen pellet therapy progestational injectable drug therapy within 6 month prior Screening . Percutaneous estrogen lotions/gels within 8 week prior Screening . Oral , topical , vaginal , patch , implantable injectable androgen therapy within 8 week prior Screening . 20 . Have reason , opinion Principal Investigator Medical SubInvestigator , would prevent subject safely participate study comply protocol requirement . 21 . Have contraindication plan study procedure ( e.g. , blood collection ) . 22 . Have participate another clinical trial within 30 day prior screen , receive investigational drug within three month prior initial dose study medication , likely participate clinical trial receive another investigational medication study .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>VVA</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Painful Sex</keyword>
</DOC>